Recruiting
Phase 2

Tofersen

Sponsor:

Washington University School of Medicine

Code:

NCT07294144

Conditions

ALS (Amyotrophic Lateral Sclerosis)

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Tofersen

Study Details

Brief summary:

The goal of this clinical trial is to evaluate whether tofersen is safe and effective in adults with non-SOD1 ALS. Tofersen is currently approved by the U.S. Food and Drug Administration to treat SOD1-ALS. The main questions it aims to answer are:

  • Does tofersen lower the levels of neurofilament light chain (NfL) in the blood and CSF of adult participants with non-SOD1 ALS?
  • Is tofersen safe and tolerable for adult participants with non-SOD1 ALS?
  • Does tofersen affect other measurements such as clinical outcomes and quality-of-life measures in participants with non-SOD1 ALS?

Participants will :

  • Receive 100mg tofersen via lumbar puncture for 24 weeks. The doses are at the following time points: Weeks 0, 2, 4, 8, 12, 16, 20, and 24.
  • Complete 2 follow-up visits following the end of the dosing period at Weeks 28 and 32.
  • Complete a variety of questionnaires and outcome measurements such as strength and breathing testing.

Conditions

ALS (Amyotrophic Lateral Sclerosis)

Study ID

NCT07294144

Start date

Dec 29, 2025

Status verified date

Jun, 2026

Completion date

May, 2028

Anticipated

Primary completion date

Jan, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use PHI in accordance with national and local participant privacy regulations.
  • Aged 18 years or older at the time of informed consent.
  • Confirmed diagnosis of ALS.
  • Time since onset of weakness due to ALS ≤ 24 months at the time of the screening visit.
  • Prior confirmed genetic testing negative for SOD1 and FUS mutations. Participants with mutations in genes other than SOD1 and FUS may be enrolled at the discretion of the Site Investigator.
  • SVC ≥ 50% of predicted value as adjusted for sex, age, and height (from the sitting position).
  • Medically able to undergo the study procedures and to adhere to the visit schedule at the time of study entry, as determined by the Investigator.
  • All participants must agree to practice effective contraception during the study and be willing and able to continue contraception for 5 months after their last dose of study treatment.
  • If taking riluzole, participant must be on a stable dose for ≥ 30 days prior to Day 1 and expected to remain at that dose until the final study visit.
  • If taking edaravone, participant must have initiated edaravone ≥ 60 days (2 treatment cycles) prior to Day 1 and expected to remain at that dose until the final study visit, unless the Investigator determines that edaravone should be discontinued for medical reasons, in which case it may not be restarted during the study.

Exclusion Criteria:

  • Treatment with another investigational drug (including investigational drugs for ALS through compassionate use or expanded access programs), biological agent, or device within 1 month or 5 half-lives of study agent, whichever is longer. Specifically, no prior treatment with small interfering RNA, stem cell therapy, or gene therapy is allowed.
  • Current enrollment in any other interventional study.
  • History of drug abuse or alcoholism within ≤ 6 months of study enrollment that would limit participation in the study, as determined by the Investigator.
  • Presence of an untreated or inadequately treated active infection requiring systemic antiviral or antimicrobial therapy at any time during the screening period.
  • Ongoing medical condition (e.g., wasting or cachexia, severe anemia) that according to the Investigator would interfere with the conduct or assessments of the study.
  • History of confounding neuromuscular or neurological disorder that is expected to have a progressive (i.e., worsening) course during the study, and/or is expected to be associated with elevations in neurofilament, in the opinion of the Investigator.
  • Female participants who are pregnant or currently breastfeeding.
  • Significant cognitive impairment, clinical dementia, or unstable psychiatric illness, including psychosis, suicidal ideation, suicide attempt, or untreated major depression ≤ 90 days, as determined by the Investigator.
  • History of allergies to a broad range of anesthetics.
  • Tracheostomy.
  • Presence of risk for increased or uncontrolled bleeding and/or risk of bleeding that is not managed optimally could place a participant at an increased risk for intraoperative or postoperative bleeding. These could include, but are not limited to, anatomical factors at or near the LP site (e.g., vascular abnormalities, neoplasms, or other abnormalities) and underlying disorders of the coagulation cascade, platelet function, or platelet count (e.g., hemophilia, Von Willebrand's disease, liver disease).
  • Anticipated need, in the opinion of the Investigator, for administration of any antiplatelet or anticoagulant medication that cannot be safely held before and/or after an LP procedure according to local or institutional guidelines and/or Investigator determination.
  • Presence of an implanted shunt for the drainage of CSF or an implanted CNS catheter.
  • Clinically significant abnormalities in hematology or clinical chemistry parameters, as determined by the Investigator, which would render the participant unsuitable for enrollment.
  • Inability to comply with study requirements.
  • Other unspecified reasons that, in the opinion of the Investigator, make the participant unsuitable for enrollment.

Study Design

Enrollment

30 participants

Anticipated

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Tofersen

Interventions

Tofersen

Tofersen 100 mg administered intrathecally.

Primary outcome measure

  • Proportion of participants with ≥30% reduction in plasma NfL [ Time Frame: From Baseline to Week 28 ]

Central Contacts and Locations

Locations

Emory University

Recruiting

Atlanta, Georgia, United States, 30322

Contacts

Karon Simmons

404-712-4182kmsimm2@emory.edu

Principal Investigator:

Jonathan Glass, MD

Massachusetts General Hospital

Recruiting

Boston, Massachusetts, United States, 02114

Contacts

Miranda Durcan

617-643-9550tofersensporadichealey@mgb.org

Principal Investigator:

Suma Babu, MBBS, MPH

Washington University ALS Center

Recruiting

St Louis, Missouri, United States, 63110

Contacts

ALS Clinical Research Team

1-844-257-2273als@wustl.edu

Principal Investigator:

Timothy M Miller, MD, PhD

More Information

Sponsor

Washington University School of Medicine

Last update posted

Jun 25, 2026

Last verified

Jun, 2026

Keywords

  • als
  • amyotrophic lateral sclerosis
  • tofersen
  • qalsody

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Washington University School of Medicine on 2026-06-25.